Quantification of K16ApoE-mediated brain-uptake of cisplatin (Cp) and methotrexate (MTX).

300 ug of the carrier peptide K16ApoE, 300 ug of cetuximab and 300 ug of cisplatin (Cp) were used in this experiment. Group 1- these animals received only Cp or MTX. Group 2- these animals received injection of K16ApoE then injection of either Cp or MTX. Group 3- these animals received an injection of K16ApoE mixed with cetuximab, followed by an injection of Cp or MTX. Group 4- these animals received an injection of K16ApoE mixed with Cp or MTX. Post-perfused brains were collected after 1 h of final injection and processed for respective assays. Fold change for Group 2 has been obtained by dividing the mean value for Group 2 by the mean value for group 1; fold change for Group 3 has been obtained by dividing the mean value for this group by the mean value of Group 1, and so on. ‘% delivery’ indicates the fraction of Cp or MTX in brain compared to the injected dose. Six animals in each group have been used.